Wed, Mar 5, 9:30 PM (52 days ago)
**Summary of Financial Performance for Aquestive Therapeutics, Inc. (AQST)** For the fiscal year ended December 31, 2024, Aquestive Therapeutics reported total revenues of $57,561,000, a 14% increase from $50,583,000 in 2023. This growth was primarily driven by a significant rise in license and royalty revenue, which surged 185% to $15,345,000, attributed to one-time deferred revenues from terminated licensing agreements. However, manufacture and supply revenue fell by 9% to $39,976,000, mainly due to decreased Suboxone sales. Net income saw a sharp increase in operating expenses, totaling $50,180,000, up 58% from the prior year, largely due to heightened commercialization efforts and R&D expenditures, particularly for Anaphylm and AQST-108. Interest expenses also rose significantly, reflecting the refinancing of debt instruments. The company is focused on advancing its product pipeline, including the recently launched Libervant for pediatric epilepsy patients, and Anaphylm, an epinephrine delivery system pending FDA approval. However, risks remain, including regulatory challenges and dependence on key customers like Indivior, which accounted for 62% of revenues in 2024. Looking ahead, Aquestive anticipates continued investment in R&D and commercialization, with a cash position of $71,546,000 as of year-end, providing a runway for operational needs. The company’s future is contingent on successful product development and navigating regulatory landscapes.